Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin.
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Interferons
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms GUARD-C
- Sponsors Roche
- 24 Apr 2013 Recruitment completion is expected on 30 Sep 2013 according to the Iranian Registry of Clinical Trials.
- 01 Nov 2012 Planned number of patients changed from 3000 to 4450 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.